Results 121 to 130 of about 576,325 (300)

Gastrointestinal disease in end-stage renal disease

World Journal of Nephrology
When kidney function declines to a point where it can no longer maintain life and requires renal replacement therapy (i.e. renal transplant or dialysis), it is called end-stage renal disease (ESRD). Patients with ESRD often experience a range of gastrointestinal (GI) symptoms, with prevalence rates reported as high as 77%-79%.
Khan, Ayesha, Mushtaq, Muhammad, Movva, Giri, Sohal, Aalam, Yang, Juliana   +4 more
openaire   +2 more sources

Nanobody‐Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

Advanced Healthcare Materials, EarlyView.
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan, Hyunseung Lee, Rema Naskar, Mi Young Cho, Hye Sun Park, Eun Hee Han, Soumyadip Hore, Sun Hee Cho, Truc Ngoc Kim Lam, Taewoong Son, Tae Jung Park, Inkyu Hwang, Jonathan L. Sessler, Kwan Soo Hong   +13 more
wiley   +1 more source

Cost-effectiveness analysis of treatment for end-stage renal disease [PDF]

, 2010
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)OBJECTIVE: End-stage renal disease (ESRD) requires costly life-sustaining therapy, either dialysis or kidney transplantation.
Eiríkur Jónsson, Gyða Ásmundsdóttir, María Heimisdóttir, Runólfur Pálsson,, Tinna Laufey Ásgeirsdóttir,   +4 more
core  

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Diabetic End-Stage Renal Disease [PDF]

New England Journal of Medicine, 1990
openaire   +2 more sources

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

A Nano‐Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast‐Immune Communication via CCL2 Sequestration

Advanced Materials, EarlyView.
A nano‐interception strategy disrupts pathogenic fibroblast–macrophage crosstalk in chronic heart failure. Scalable Prussian blue nanoparticles selectively sequester CCL2 via ultrahigh‐affinity binding, preventing CCR2+ macrophage recruitment and breaking a key fibro‐inflammatory circuit. This approach demonstrates robust efficacy in murine and porcine
Bo Chen, Gao Wei, Guowei Zeng, Haoyu Li, Rongrong Wu, Hongyu Yan, Zijie Zhou, Kai Luo, Xiaoyang Zhang, Cong Li, Longming Huang, Lingyan Cheng, Xinjie Zhang, Jinghao Zheng, Bozhong Shi, Xiaojun Cai, Xiaomin He   +16 more
wiley   +1 more source

Vitamin C and functional iron deficiency anemia in hemodialysis

Kidney Research and Clinical Practice, 2012
Yong-Lim Kim
doaj   +1 more source

Efficacy and Safety Assessment of 5‐Fluorouracil, Irinotecan and Oxaliplatin‐Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy

Advanced Materials, EarlyView.
A novel FIRINOX‐loaded implant demonstrates controlled drug release, and potent therapeutic efficacy in pancreatic ductal adenocarcinoma mouse models with safety confirmed in a large‐animal pre‐clinical model. This innovative drug delivery platform offers a promising new treatment approach for non‐resectable, treatment‐resistant pancreatic cancer ...
Samantha J. Wade, Ashna A. Kumar, Samuel O. Nitschke, Paul Joyce, Elahe Minaei, Stephanie E. Reuter, Chelsea Penney, Holly Warren, Ruby Shepherd, Jeremy N. Dinoro, Gordon G. Wallace, Anthony Dosseto, Sameera Ansar, Naila Islam, Alistair Lochhead, George Sharbeen, Phoebe A. Phillips, Morteza Aghmesheh, Wayne J. Hawthorne, Kara L. Vine‐Perrow   +19 more
wiley   +1 more source

Resistant hypertension in pediatric end stage renal disease [PDF]

Farmacia Hospitalaria, 2014
Virginia Martínez-Santana, Olalla Álvarez, Silvia Marique-Rodríguez, Ana Belén Martínez   +3 more
doaj   +1 more source